TELA Bio (NASDAQ: TELA) CMO details stock and option holdings

Rhea-AI Filing Summary

TELA Bio, Inc. Chief Medical Officer Howard N. Langstein filed an initial statement of holdings. He directly holds 71,347 shares of common stock and a stock option covering 72,750 shares at an exercise price of $0.7830 per share, expiring on February 18, 2036. The option vests 25% on February 18, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Langstein Howard N.

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 72,750 shares (Direct); Common Stock — 71,347 shares (Direct)

Footnotes (1)

1. F1. The option vests 25% on February 18, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 03/11/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What did TELA Bio (TELA) disclose about Howard N. Langstein’s holdings?

TELA Bio disclosed that Chief Medical Officer Howard N. Langstein filed an initial ownership report. He holds 71,347 shares of common stock and a stock option linked to 72,750 underlying shares, providing potential future equity exposure in the company.

How many TELA Bio (TELA) shares does the CMO directly own?

Howard N. Langstein directly owns 71,347 shares of TELA Bio common stock. This figure reflects his reported direct equity position and serves as a baseline for future insider activity reported in subsequent regulatory filings.

What are the key terms of Howard N. Langstein’s TELA Bio stock option?

Langstein holds a stock option tied to 72,750 shares of TELA Bio common stock at an exercise price of $0.7830 per share. The option expires on February 18, 2036, giving him a long-dated opportunity to acquire additional shares.

How does the TELA Bio (TELA) CMO’s stock option vest?

The option vests 25% on February 18, 2027. The remaining 75% vests in equal monthly installments over the next 36 months, conditioned on Langstein’s continued service through each applicable vesting date.

Does this TELA Bio filing show any insider buying or selling?

The report lists existing holdings and option terms but does not show any buy or sell transactions. It functions as an initial statement of beneficial ownership for the Chief Medical Officer, rather than recording market trades.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Langstein Howard N.

(Last) (First) (Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN PA 19355

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2026

3. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	71,347	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	02/18/2036	Common Stock	72,750	$0.783	D

Explanation of Responses:

1. The option vests 25% on February 18, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Megan Smeykal, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.